SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following a launch failure where Blue Origins rocket placed the BlueBird 7 satellite into an unusable, off-nominal orbit, prompting investors to debate the company's reliance on launch partners versus its long-term commercial potential. While some in the community see the sharp sell-off as a strategic buying opportunity due to insurance coverage and intact fundamentals, others are expressing frustration over management's communication and the potential impact on future launch cadence.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining intense investor attention as participants speculate on imminent data readouts from the REGAL Phase 3 trial and upcoming AACR conference presentations for SLS009. The community is deeply divided, with bulls pointing to extended survival signals and institutional positioning as catalysts for a potential squeeze, while bears highlight concerns over trial design and the company's long-term financial viability.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is capturing significant community attention as it aligns its brand with 420 culture, driven by a series of ongoing digital events and a push toward long-term ecosystem development. Supporters are actively engaging in the projects community spaces and scavenger hunts, framing the asset as a culture-driven alternative to traditional market tokens.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as a major beneficiary of the AI infrastructure super-cycle, driven by a surge in demand for optical interconnects and custom silicon. The community is actively discussing its potential for continued growth, buoyed by strategic partnerships and analyst sentiment positioning it as a core player in next-generation AI hardware.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing massive momentum and high volatility due to a favorable executive order from the Trump administration that aims to fast-track research and federal funding for ibogaine treatments. The community is actively discussing a potential short squeeze, citing the stock's exceptionally low float, while debates persist between bulls betting on triple-digit gains and bears warning of a potential pump-and-dump scenario.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as frustrated investors discuss the relentless rally in semiconductor stocks, which has driven this leveraged bear ETF to new lows. The community is actively debating whether the current market environment is a parabolic blow-off top driven by AI exuberance and geopolitical distractions, or if they should continue averaging down in anticipation of a sharp sector pullback.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility as investors clash over whether the recent price surge represents a legitimate breakout tied to global event expansion or a classic pump-and-dump scheme. The community is deeply divided, with some traders highlighting successful price action while others aggressively warn of manipulation, potential rug-pull risks, and the dangers of chasing hype in the memecoin space.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is rallying after receiving formal Greenland government approval to increase its stake in the Tanbreez rare earth project to 92.5%, a major catalyst that strengthens its control over a key Western supply chain asset. Community sentiment is overwhelmingly bullish, with active discussions focusing on high short interest, the potential for a gamma squeeze, and the stock's long-term strategic value for space and defense technology.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as the market reacts to the White House executive order aimed at accelerating FDA review and research funding for psychedelic treatments, with many in the community viewing the directive as a major regulatory catalyst for the sector. Investors are actively discussing the company's status as a leader with completed Phase 3 trials, while debating potential risks like share dilution and the ongoing competitive landscape for mental health therapies.

Operates as a holding company with interest in providing social shopping platform solutions

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings is experiencing intense volatility as retail traders push the stock through significant intraday swings, drawing heavy attention to its low-float status and high short interest. While bulls are banking on a potential short squeeze and upcoming earnings catalysts, the community remains deeply divided, with many debating whether the rapid price movements signal real growth or are merely a classic pump-and-dump cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>LCID slid for a third straight day after TD Cowen and Baird trimmed their price targets following recent company updates and capital raises.</li><li>ABT dropped after cutting its 2026 EPS outlook to $5.38-$5.58 due to the impact of its $23 billion acquisition of Exact Sciences.</li><li>ASBP slumped after shareholders approved a reverse stock split and authorized additional equity issuance tied to preferred-stock conversion and financing deals.</li></ul>Shares of Lucid Group (LCID), Abbott Laboratories (ABT) and Aspire Biopharma Holdings (ASBP) dropped to fresh 52-week lows Thursday, bucking a broader market rally, as investors weighed softer growth prospects and dilution risks across the three companies.On Thursday,&nbsp;<a href="https://stocktwits.com/symbol/LCID">LCID</a> and&nbsp;<a href="https://stocktwits.com/symbol/ABT">ABT</a> shares each fell about 6%, while&nbsp;<a href="https://stocktwits.com/symbol/ASBP">ASBP</a> slumped 45%.<h2 class="st-heading-2">LCID Falls As Outlook Confidence Wavers</h2>LCID shares fell 6% on Thursday, extending their decline to a third straight session, after multiple Wall Street firms lowered price targets following recent company updates in a weaker auto market.&nbsp;Earlier this week, TD Cowen analyst Itay Michaeli cut the firm’s price target to $10 from $19 and maintained a ‘Hold’ rating, saying automakers appear better positioned than suppliers in the first quarter (Q1) to provide investors with outlook “reassurances and retaining guidance credibility.” The brokerage added that guide-down risk across the sector remains low.Baird also lowered its price target to $12 from $14 and kept a ‘Neutral’ rating after updating its model following the appointment of a permanent CEO and expansion of Lucid’s partnership with Uber.Investor sentiment has also remained under pressure from a recent $1.05 billion capital raise and a $300 million stock offering. The company is targeting production of 25,000 to 27,000 vehicles in 2026, but produced 5,500 vehicles and delivered 3,093 units in Q1 after deliveries were temporarily affected by a Gravity SUV seat-belt recall.<h2 class="st-heading-2">ABT Slides On Exact Sciences Impact To Bottomline</h2>ABT shares posted their worst session in nearly three months on Thursday after the company lowered its 2026 adjusted profit outlook due to the impact of its $23 billion acquisition of Exact Sciences.Abbott cut its full-year outlook and now expects adjusted earnings per share of $5.38 to $5.58, down from its earlier forecast of $5.55 to $5.8. Investors focused on softer organic growth trends, weakness in the nutrition segment and slower-than-expected momentum in diabetes and structural-heart devices, facing competition from Edwards Lifesciences.Evercore ISI lowered its price target to $120 from $134, saying organic growth came in “a tad below” expectations and base organic guidance was effectively reduced by about 50 basis points.However, Abbott said that the $23 billion acquisition of Exact Sciences is expected to contribute about $3 billion in incremental sales this year and support longer-term growth as Abbott continues to shift away from declining COVID testing revenue.<h2 class="st-heading-2">ASBP Slumps On Dilution Concerns</h2>ASBP shares remained under pressure after stockholders approved several proposals expanding the company’s flexibility to issue additional equity and restructure its capital base.At a special meeting earlier this month, investors approved a reverse stock split within a range of 1-for-5 to 1-for-500 and authorized the issuance of conversion shares tied to Series A preferred stock. Stockholders also approved additional equity issuance under an existing purchase agreement with Arena Business Solutions Global SPC II. A proposal to increase the authorized common shares from 490 million to 700 million was also approved.The company separately completed a preferred-stock financing tranche, generating about $10 million in proceeds, while converting part of its outstanding debt into equity, underscoring investor concerns around dilution risk and huge funding needs.Additionally, Aspire entered a letter of intent to acquire Dura Driver Control Systems in a $30 million deal to expand its footprint beyond drug delivery.<h2 class="st-heading-2">How Do Retail Traders Feel About LCID, ABT, ASBP?</h2>On Stocktwits, retail sentiment for LCID and ABT was ‘extremely bullish’ amid ‘extremely high’ message volume, while sentiment for ASBP was ‘bullish’ with ‘extremely high’ message volume.Over the past year, LCID shares have declined 67%, ABT is down 25%, and ASBP has plunged 99%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-outpaces-2025-gains-battery-swap-rollout-focus/cZJUf82RIx7">Nio Stock Already Outruns Last Year’s Gains — Now A Massive Battery-Swap Push Is Coming Into Spotlight</a>

In this photo illustration, the logo of Lucid Group, Inc. is displayed on a smartphone screen, with a stock market chart in the background, on May 4, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

LCID, ABT, ASBP Stocks Hit 52-Week Lows Today: What’s Driving The Selloff?

LCID and ABT each fell about 6% on Thursday, while ASBP plunged 45%, bucking a broader market rally.

Equity

<ul class="summary-bullets"><li>Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial.</li><li>The firm said OTASA demonstrated faster and higher absorption of acetylsalicylic acid compared with chewed aspirin tablets.</li><li>The company said that&nbsp;&nbsp;Early safety evaluations showed the product was well tolerated, with no adverse events reported.</li></ul>Shares of Aspire Biopharma Holdings (ASBP) shot up 32% on Wednesday after the company said it received favorable feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-investigational new drug (IND) meeting for OTASA, its high-dose sublingual (under-the-tongue) aspirin aimed at emergency treatment of suspected heart attacks.The FDA’s feedback supports a planned Section 505(b)(2) New Drug Application (NDA) submission in the second half of 2026, the company added.Based on the agency’s guidance, Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial. The study will enroll 32 healthy volunteers and compare OTASA 162 mg with the current standard of care, two chewed 81 mg aspirin tablets, by measuring inhibition of serum thromboxane B2, a marker linked to blood clotting.The pre-IND submission was supported by encouraging pilot clinical data. Aspire said OTASA demonstrated faster and higher absorption of acetylsalicylic acid compared with chewed aspirin tablets. The sublingual formulation also achieved rapid platelet inhibition, reducing thromboxane B2 levels within the first two minutes after administration. Early safety evaluations showed the product was well tolerated, with no adverse events reported.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/ASBP">ASBP</a> remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/ASBP_jpg_d2fe432dd1.webp" alt="ASBP.jpg" width="906" height="105"><figcaption>&nbsp;</figcaption></figure>Users speculated that the company could already be engaged in licensing negotiations.<stembedurl>https://stocktwits.com/juned/message/641088627</stembedurl><stembedurl>https://stocktwits.com/Pennystockmadness/message/641086670</stembedurl><h2 class="st-heading-2">Stock Price</h2>The update and the subsequent rally in stock price come at a time when the company has been dealing with listing concerns stemming from its low share price. In November, investors approved a proposal allowing the board to implement a reverse stock split at a ratio of 1-for-5 to 1-for-40, within one year if needed.The company has also secured Nasdaq approval to remain listed, contingent on meeting minimum bid price and equity requirements by late January and mid-February 2026.At present, the stock is trading near the $0.14 mark.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/silver-falls-ahead-of-index-fund-rebalancing/cmxz3OLR420">Silver Tumbles 5% Amid Profit-Booking And&nbsp;Scheduled Reshuffling Of Commodity Index Funds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin –  Retail Expects Licensing Negotiations Soon

The FDA’s feedback supports a planned new drug application submission in the second half of 2026.

Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company was founded on February 2, 2025 and is headquartered in Estero, FL.

Current Price	$0.2697
Prev Close	$0.30
Open	$0.291
Dividend Yield	0.00%
50-Day Moving Average	$1.14
Beta	1.41
Avg. Volume	550,421.02
PE Ratio	-0.01

52-Week High	$35.01
52-Week Low	$0.2522
Market Capitalization	$1.36M
EPS (Annual)	-$16.38
Price to Book	-0.15
Revenue Per Employee	N/A

ASBP
Aspire Biopharma Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ASBP News

ASBPAspire Biopharma Holdings Inc